Grifols S.A.

Products

Category

Product

Brand

Description

Biologic Therapeutic Drugs (BIO079E)

Xembify		Xembify is Grifols’ first 20% immune globulin for the subcutaneous treatment of primary humoral immune deficiency disease in patients two years of age and older. It was approved by the Food and Drug Administration on July 4, 2019. Xembify represents a valuable addition to the Grifols portfolio for primary humoral immune deficiency disease (PIDD)
Albutein		The drug is having two different concentration one with 25% sterile, and other with 5% sterile aqueous solution for single-dose intravenous administration containing 25% human albumin and 5% human albumin respectively (weight/volume).
AlphaNine SD		A high-purity factor IX product for patients with hemophilia B.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment